Skip to main content

Tricuspid-Valve Intervention in Heart Failure.

The New England journal of medicine

Authors: Jörg Hausleiter, Thomas J Stocker, Tobias Geisler, Philipp Lurz, Wolfgang Rottbauer, Edith Lubos, Niklas Schofer, Christian Frerker, Johanne Frank, Holger Thiele, Rico Osteresch, Volker Rudolph, Alexander Lauten, Erion Xhepa, Jürgen Rothe, Tienush Rassaf, Stephan Baldus, Georg Nickenig, David M Leistner, Eike Tigges, Victoria Kehl, Mirjam Kessler, Tobias Kister, Tobias Ruf, Muhammed Gerçek, Meinrad Gawaz, Derk Frank, Ingo Eitel, Ralph Stephan von Bardeleben, Daniel Kalbacher, Osama Soliman, Michael Näbauer, Steffen Massberg

BACKGROUND: The effect of transcatheter tricuspid-valve repair on clinical outcomes, including death and hospitalization for heart failure, in patients with severe tricuspid regurgitation remains uncertain.

METHODS: We randomly assigned patients with symptomatic severe tricuspid regurgitation and an increased risk of future heart-failure events in a 2:1 ratio to tricuspid-valve repair plus medical therapy (tricuspid-repair group) or medical therapy alone (medical-therapy group). The first primary end point was a hierarchical composite of death from any cause, hospitalization for heart failure, and quality-of-life improvement at 1 year, assessed by win ratio. If the between-group difference was significant, a second primary end point would be tested: a composite of death from any cause or hospitalization for heart failure through 3 years.

RESULTS: A total of 360 patients underwent randomization (237 patients were assigned to the tricuspid-repair group and 123 to the medical-therapy group). The mean (±SD) age of the patients was 80.3±6.4 years, and 56.4% were women. The win ratio for the first primary end point was 2.42 (95% confidence interval [CI], 1.76 to 3.33; P<0.001), favoring tricuspid-valve repair. The Kaplan-Meier estimate for freedom from death from any cause or hospitalization for heart failure (second primary end point) through 3 years was 52.4% (95% CI, 43.2 to 63.6) in the tricuspid-repair group and 21.0% (95% CI, 12.7 to 34.6) in the medical-therapy group (hazard ratio for death from any cause or hospitalization for heart failure, 0.40; 95% CI, 0.29 to 0.55; P<0.001). Major adverse events within 30 days occurred in 14 patients (5.9%) in the tricuspid-repair group.

CONCLUSIONS: Among patients with symptomatic severe tricuspid regurgitation, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone with respect to a hierarchical composite of death from any cause, hospitalization for heart failure, and quality-of-life improvement at 1 year and was also associated with a lower risk of a composite of death from any cause or hospitalization for heart failure through 3 years. (Funded by the German Center for Cardiovascular Research and others; TRIC-I-HF ClinicalTrials.gov number, NCT04634266.).

Copyright © 2026 Massachusetts Medical Society.

PMID: 42670975

Participating cluster members